TPS cannot be differentiated between responders and non-responders to nivolumab monotherapy in some malignancies [29, 30]; however, PD-L1 positivity has a modest survival benefit after nivolumab administration in ESCC [2]. Here, CD274 is linked to esophageal squamous cell carcinoma.